|
1
|
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
|
J Hypertens
|
2013
|
18.17
|
|
2
|
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
|
Eur Heart J
|
2013
|
12.73
|
|
3
|
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension.
|
Blood Press
|
2013
|
2.62
|
|
4
|
Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors.
|
J Clin Hypertens (Greenwich)
|
2012
|
2.03
|
|
5
|
Reproducibility of the circadian blood pressure pattern in 24-h versus 48-h recordings: the Spanish Ambulatory Blood Pressure Monitoring Registry.
|
J Hypertens
|
2007
|
1.62
|
|
6
|
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.
|
J Hypertens
|
2011
|
1.57
|
|
7
|
[Prevalence of target organ damage and metabolic abnormalities in resistant hypertension].
|
Med Clin (Barc)
|
2011
|
1.42
|
|
8
|
Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study.
|
Eur Heart J
|
2013
|
1.37
|
|
9
|
Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial.
|
J Hypertens
|
2014
|
1.03
|
|
10
|
Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.
|
Am J Cardiol
|
2004
|
0.94
|
|
11
|
'Multiple action fixed combination. Present or future?'.
|
Fundam Clin Pharmacol
|
2009
|
0.88
|
|
12
|
Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence.
|
J Hypertens
|
2014
|
0.85
|
|
13
|
Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression.
|
J Hypertens
|
2014
|
0.84
|
|
14
|
Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke.
|
J Hypertens
|
2016
|
0.83
|
|
15
|
Clinical characteristics of isolated clinic hypertension.
|
J Hypertens
|
2008
|
0.82
|
|
16
|
AT1 blockers and uric acid metabolism: are there relevant differences?
|
J Hypertens Suppl
|
2002
|
0.82
|
|
17
|
Should hypertension guidelines be changed for hypertensive patients with the metabolic syndrome?
|
J Clin Hypertens (Greenwich)
|
2007
|
0.80
|
|
18
|
Prevalence of renal insufficiency in individuals with hypertension and obesity/overweight: the FATH study.
|
J Am Soc Nephrol
|
2006
|
0.79
|
|
19
|
[Ambulatory blood pressure monitoring (CABPM): clinical characteristics of 31,530 patients].
|
Med Clin (Barc)
|
2007
|
0.77
|
|
20
|
Antihypertensive therapy in patients with metabolic syndrome.
|
Curr Opin Nephrol Hypertens
|
2006
|
0.76
|
|
21
|
A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide.
|
Vasc Health Risk Manag
|
2013
|
0.75
|
|
22
|
One step forward for serelaxin as a promising therapy in cardiac fibrosis.
|
Hypertension
|
2014
|
0.75
|
|
23
|
Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial.
|
Am J Hypertens
|
2002
|
0.75
|
|
24
|
[Recent evidence of support to arterial hypertension treatment guides].
|
Med Clin (Barc)
|
2008
|
0.75
|
|
25
|
[Renal function protection in type 2 diabetic patients].
|
Med Clin (Barc)
|
2002
|
0.75
|
|
26
|
[New targets in patients with cardiometabolic risk].
|
Med Clin (Barc)
|
2007
|
0.75
|
|
27
|
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.
|
Expert Opin Pharmacother
|
2005
|
0.75
|
|
28
|
24-h pulse pressure cutoff point definition by office pulse pressure in a population of Spanish older hypertensive patients.
|
J Hypertens
|
2017
|
0.75
|
|
29
|
[Stratification and degree of control of cardiovascular risk factors in hypertensive Spanish population. Results of the DICOPRESS study].
|
Med Clin (Barc)
|
2007
|
0.75
|
|
30
|
[Selective inhibitors of cyclooxigenase-2 (Coxibs) and cardiovascular morbidity].
|
Med Clin (Barc)
|
2002
|
0.75
|
|
31
|
[Can we achieve a greater reduction of cardiovascular mortality and morbidity in patients already treated with renin-angiotensin system blockers?].
|
Med Clin (Barc)
|
2009
|
0.75
|
|
32
|
Management of cardiovascular risk factors in patients with metabolic syndrome.
|
Cardiovasc Hematol Agents Med Chem
|
2007
|
0.75
|
|
33
|
[Effectiveness and safety of calcium antagonists in hypertensive patients].
|
Med Clin (Barc)
|
2005
|
0.75
|
|
34
|
[Effectiveness of antihypertensive treatment and control of blood pressure: is it improvable?].
|
Med Clin (Barc)
|
2013
|
0.75
|